Options
Opinion on the impact of nonāmonotonic dose responses on EFSA's human health risk assessments
Date Issued
2021-10
Date Available
2022-08-29T14:38:16Z
Abstract
This Opinion assesses the biological relevance of the non-monotonic dose responses (NMDR) identified in a previous EFSA External Report (Beausoleil et al., 2016) produced under GP/EFSA/SCER/2014/01 and the follow-up probabilistic assessment (Chevillotte et al., 2017a,b), focusing on the in vivo data sets fulfilling most of the checkpoints of the visual/statistical-based analysis identified in Beausoleil et al. (2016). The evaluation was completed with cases discussed in EFSA assessments and the update of the scientific literature. Observations of NMDR were confirmed in certain studies and are particularly relevant for receptor-mediated effects. Based on the results of the evaluation, the Opinion proposes an approach to be applied during the risk assessment process when apparent non-monotonicity is observed, also providing advice on specific elements to be considered to facilitate the assessment of NMDR in EFSA risk assessments. The proposed approach was applied to two case studies, Bisphenol A and bis(2-ethylhexyl phthalate (DEHP) and these evaluations are reported in dedicated annexes. Considering the potential impact of NMDRs in regulatory risk assessment, the Scientific Committee recommends a concerted international effort on developing internationally agreed guidance and harmonised frameworks for identifying and addressing NMDRs in the risk assessment process.
Type of Material
Journal Article
Publisher
Wiley
Journal
EFSA Journal
Volume
19
Issue
10
Copyright (Published Version)
2021 European Food Safety Authority
Language
English
Status of Item
Peer reviewed
ISSN
1831-4732
This item is made available under a Creative Commons License
File(s)
Owning collection
ScopusĀ© citations
18
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Views
215
Last Week
1
1
Last Month
1
1
Acquisition Date
Mar 28, 2024
Mar 28, 2024
Downloads
210
Last Week
2
2
Last Month
24
24
Acquisition Date
Mar 28, 2024
Mar 28, 2024